Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
Tensegrity Pharma has raised $966K in total funding. The most recent round was Seed. The last funding was announced in January 2025.
Tensegrity Pharma's investors include Mitsubishi UFJ Capital, Newton Biocapital.
Tensegrity Pharma is headquartered in Tokyo, Japan.
Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
Tensegrity Pharma is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tensegrity Pharma — Funding & Investors." VCBacked, January 31, 2025, https://www.vcbacked.co/company/tensegrity-pharma. Accessed August 14, 2026.
VCBacked. (2025). Tensegrity Pharma — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/tensegrity-pharma
{{cite web |title=Tensegrity Pharma — Funding & Investors |url=https://www.vcbacked.co/company/tensegrity-pharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated